In the past week, bluebird bio named new leaders after its acquisition, Dyne secured a debt deal and ProFound Therapeutics ...

Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

Swiss pharma giant Novartis has announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab ...